Case Studies

THE CHALLENGE

A biotechnology spin-off had developed a targeted drug-delivery platform based on functionalized nanoparticles designed to improve therapeutic delivery. Promising early-stage in-vitro results provided a strong scientific foundation, but the company needed a clearer path from technical validation to commercial development.

The founders required a structured understanding of the competitive landscape, development considerations, potential pharmaceutical partners and the evidence needed to support future partnering and financing discussions.

THE APPROACH

Biotech Asset De-Risking & Commercialization Strategy

The available pre-clinical data and supporting documentation were reviewed from a strategic and commercial perspective.

Relevant pharmaceutical pipelines and competing technology approaches were assessed to identify potential areas of differentiation and partnership opportunity. Key development and regulatory considerations were incorporated into the commercialization roadmap, alongside factors such as clinical translation, safety, manufacturing scalability and potential partner requirements.

The resulting strategy connected scientific progress with the evidence and positioning required for institutional business-development discussions.

THE VALUE DELIVERED

The platform was repositioned from an early-stage scientific technology into a more structured and commercially articulated development opportunity.

This positioning supported the company's engagement with external partners and contributed to securing an international co-development partnership that provided funding for subsequent pre-clinical milestones.

THE CHALLENGE

A specialized medical-device developer had engineered a biocompatible surface coating intended to reduce thrombosis risk in next-generation cardiovascular implants.

Although laboratory validation had demonstrated the technology's potential, the company needed to connect its technical evidence with the clinical, regulatory and commercial considerations relevant to prospective MedTech partners.

In particular, management needed greater clarity around how the European MDR environment, clinical validation expectations and manufacturer risk considerations could influence the technology's development and commercial positioning.

THE APPROACH

Clinical & Commercial Ecosystem Alignment

The available technical data and development documentation were reviewed to identify the evidence most relevant to prospective industry partners.

Clinical validation considerations and the broader European MDR landscape were assessed from a strategic and commercialization perspective. The technology's value proposition was then refined around the clinical and commercial risk considerations relevant to established cardiovascular-device manufacturers.

The objective was to create a clearer connection between the technology's scientific performance, its development pathway and the requirements of potential strategic partners.

THE VALUE DELIVERED

The resulting positioning strengthened the company's ability to communicate the technology's clinical and commercial relevance to established industry participants.

The engagement supported the progression of discussions with a global cardiovascular implant manufacturer, culminating in an exclusive joint-development agreement within 11 months.

THE CHALLENGE

A life-sciences venture had developed a novel bio-fermented active ingredient with promising potential for premium cosmetic applications.

The company had established encouraging laboratory safety and efficacy data but needed to bridge the gap between biotechnology development and the commercial requirements of premium cosmetics companies.

This required a clearer understanding of market positioning, pricing, formulation and supply-chain considerations, sustainability expectations, competitive differentiation and the requirements of prospective strategic partners.

THE APPROACH

Premium Brand Value-Stream & Market Integration

Rather than positioning the technology primarily as a commodity ingredient, the commercialization strategy focused on its potential as a differentiated premium active.

Target markets and prospective partners were assessed, and a focused go-to-market strategy was developed around scientific differentiation, value-based pricing, supply-chain considerations and premium-market requirements.

IP positioning and protection considerations were incorporated into the broader commercialization roadmap to support long-term differentiation, while relevant safety, formulation and market-entry considerations were reflected in the partner strategy.

THE VALUE DELIVERED

The resulting positioning strengthened the ingredient's commercial proposition and supported direct engagement with strategically relevant premium-market partners.

The commercialization process contributed to an exclusive development and licensing agreement with a major European luxury cosmetics group within 12 months of market launch, representing a multi-million-euro commercial opportunity.

THE CHALLENGE

A specialized deep-tech venture had developed a next-generation molecular technology with the potential to improve product stability and synthesis efficiency.

The underlying science was promising, but the company faced a familiar commercialization challenge: securing its first major enterprise customer.

To progress from technical validation to commercial adoption, management needed to translate scientific performance into a clear economic value proposition while addressing the technical, commercial and procurement requirements of a large multinational customer.

THE APPROACH

Enterprise Go-to-Market & Pricing Strategy

The available performance and validation data were assessed alongside the prospective customer's operational requirements to identify the technology's potential economic and performance benefits.

A value-based commercialization framework was then developed, including enterprise pricing scenarios, technical positioning, data-room preparation and commercial licensing considerations.

The strategy was designed to balance the requirements of an initial anchor customer with the company's longer-term commercial and intellectual-property objectives.

THE VALUE DELIVERED

The venture secured its first anchor commercial agreement with a major multinational corporation.

The agreement provided important external commercial validation for the technology and established a stronger foundation for subsequent enterprise-market development and international expansion.

THE CHALLENGE

A multinational food-processing company was generating substantial volumes of organic side-streams that were costly to manage and offered limited economic value in their existing form.

Management wanted to explore whether scientifically valuable compounds within these streams could be recovered, stabilized and repositioned for higher-value commercial applications.

The challenge required both scientific understanding of the underlying biomass and market intelligence capable of identifying commercially attractive applications outside the company's traditional value chain.

THE APPROACH

Cross-Industry Valorization & Market Integration

The composition and potential value of the biomass streams were assessed to identify promising classes of higher-value compounds.

A commercialization and scale-up framework was then developed around the potential conversion of selected side-streams into higher-value ingredients.

In parallel, market opportunities were assessed across premium cosmetics and functional beverage applications. The analysis incorporated potential customer requirements, relevant safety and market-entry considerations, supply-chain requirements, sustainability positioning and value-based pricing.

THE VALUE DELIVERED

The initiative created a pathway for transforming a costly industrial side-stream into a potential source of commercial value.

By connecting the company's existing industrial processes with higher-value cosmetics and beverage applications, the project supported the development of new B2B supply opportunities and a stronger circular-economy proposition.

Within 16 months, the initiative contributed to commercial supply agreements and materially reduced the economic burden associated with the original waste stream.

THE CHALLENGE

An institutional investor was evaluating the acquisition of a growth-stage company specializing in advanced functional polymers.

Before proceeding with the transaction, the investment committee required an independent technical perspective on whether the target company's laboratory-stage technology and supporting scientific documentation provided a credible basis for commercial-scale production.

The assessment needed to identify material technical assumptions, scale-up risks and areas requiring further investigation before capital was committed.

THE APPROACH

Pre-Investment Technical Due Diligence

A structured review of the target company's technical data room and supporting documentation was conducted.

The assessment focused on laboratory-to-production scale-up assumptions, process robustness, technical dependencies and potential constraints affecting commercial implementation.

Key technical risks, uncertainties and areas requiring additional validation were identified and translated into decision-relevant considerations for the investment committee.

The technical assessment formed one input into the client's broader commercial, financial and legal due-diligence process.

THE VALUE DELIVERED

The investment committee received an independent technical assessment of the asset's scale-up potential, principal technical assumptions and identified risk factors.

The analysis provided an additional evidence base for the client's investment decision and informed its evaluation of the proposed multi-million-euro acquisition and transaction terms.